Cannabidiorcol

Cannabidiorcol (CBDO, CBD-C1, O-1821) is related to cannabidiol, with the pentyl side chain shortened to a methyl group. Cannabidiorcol has low affinity for cannabinoid receptors (CBs) and is an agonist of the transient receptor potential channel (TRP channel), through which it produces antiinflammatory effects, but can also promote tumorigenesis at high concentrations[1][2].

Product Specifications

CAS Number

[35482-50-9]

Product Name Alternative

O-1821; CBD-C1

UNSPSC

12352005

Hazard Statement

H225, H302+H312+H332, H319

Target

TRP Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cannabidiorcol.html

Concentration

38.70 mM * 100 μL in Acetonitrile

Purity

99.0

Solubility

10 mM in DMSO

Smiles

OC1=C([C@H]2[C@@H](CCC(C)=C2)C(C)=C)C(O)=CC(C)=C1

Molecular Formula

C17H22O2

Molecular Weight

258.36

Precautions

H225, H302+H312+H332, H319

References & Citations

[1]Teresina Laragione, et al. Combination therapy of a TRPV2 agonist with a TNF inhibitor achieves sustained suppression of disease severity and reduced joint damage. Clin Exp Immunol. 2023 Mar; 211 (3) : 233–238.|[2]Rongqi Huang, et al. Thermal stress involved in TRPV2 promotes tumorigenesis through the pathways of HSP70/27 and PI3K/Akt/mTOR in esophageal squamous cell carcinoma. Br J Cancer. 2022 Nov 1; 127 (8) : 1424–1439.